1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,373 | 0,404 | 28.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Tevogen Bio Inc: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q | 158 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended... ► Artikel lesen | |
| 14.11. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 05.11. | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | 84 | GlobeNewswire (Europe) | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| 03.11. | Tevogen Bio Inc: Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn | 90 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported... ► Artikel lesen | |
| 29.10. | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 320 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| 15.10. | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 317 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| 26.09. | Tevogen Bio Holdings verstößt gegen NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| 26.09. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 175 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
| 23.09. | Tevogen Bio Inc: Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID | 1 | GlobeNewswire (USA) | ||
| 19.09. | Tevogen Bio Inc: Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans | 1 | GlobeNewswire (USA) | ||
| 10.09. | Tevogen Bio Inc: Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston | 1 | GlobeNewswire (USA) | ||
| 09.09. | Tevogen Bio Inc: Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection | 123 | GlobeNewswire (Europe) | Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")... ► Artikel lesen | |
| 08.09. | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 2 | Investing.com | ||
| 08.09. | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 193 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to... ► Artikel lesen | |
| 04.09. | Tevogen shares EBV treatment forecast with $3.5 billion revenue potential | 2 | Investing.com | ||
| 04.09. | Tevogen Bio Inc: Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas | 129 | GlobeNewswire (Europe) | The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could... ► Artikel lesen | |
| 03.09. | Tevogen highlights need for SARS-CoV-2 treatments for immunocompromised | 2 | Investing.com | ||
| 03.09. | Tevogen Bio Inc: Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 | 125 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals... ► Artikel lesen | |
| 27.08. | Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure | 150 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under... ► Artikel lesen |
1 2 3 4 5 Weiter >>
81 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AMGEN | 297,95 | +0,15 % | Pharma Deutschland erweitert Vorstand auf Mitgliederversammlung 2025 / Mitgliederversammlung wählt Hatice Camdere (Amgen GmbH), Susanne Lamminger (HexalAG/Sandoz) und Christian Thams (Johnson&Johnson) | Berlin (ots) - Auf der 71. Mitgliedersammlung von Pharma Deutschland wurden drei neue Vorstandsmitglieder berufen. Die neuen Vorstandsmitglieder sind Hatice Camdere (Amgen GmbH), Susanne Lamminger (Hexal... ► Artikel lesen | |
| NOVAVAX | 6,087 | +0,40 % | NOVAVAX INC zittert - jetzt entscheidet sich alles! | ||
| PALATIN TECHNOLOGIES | 19,400 | +14,12 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 670,20 | -0,39 % | EU-Zulassung für Dupixent bringt neuen Schwung für Sanofi und Regeneron: Sanofi und Regeneron starten durch, nachdem Dupixent bei Hauterkrankung grünes Licht erhält | Die EU-Kommission hat eine entscheidende Zulassungserweiterung für das Entzündungsmedikament Dupixent erteilt. Sanofi und Regeneron rücken mit dieser Zulassung in den Fokus von Anlegern.Regulatorischer... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,660 | -5,14 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,580 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 48,010 | -0,37 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 45,070 | -0,44 % | AKTIONÄR-Jahresfavorit Arrowhead außer Rand und Band: Knoten geplatzt | Die Biotech-Branche befindet sich wieder spürbar im Aufwind. Allein am gestrigen Mittwoch konnte die Aktie von Arrowhead Pharmaceuticals mit einem Plus von gut 23 Prozent für Aufsehen sorgen. Nach der... ► Artikel lesen | |
| XOMA ROYALTY | 27,400 | -1,44 % | Mural Oncology plc: Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty | WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,270 | +3,25 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ORAGENICS | 0,880 | -6,30 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +7,77 % bei einem Aktienkurs von 0,416 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.